6-K/A

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 6-K/A

(Amendment No. 1)

REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 UNDER
THE SECURITIES EXCHANGE ACT OF 1934

For the month of December 2018

Commission File Number: 001-34541

GLOBAL CORD BLOOD CORPORATION

(Translation of registrant’s name into English)

48th Floor, Bank of China Tower
1 Garden Road
Central
Hong Kong S.A.R.
(Address of Principal Executive Offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F x                           Form 40-F o

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): o

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): o

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes o                           No x

If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-               .

EXPLANATORY NOTE

This Amendment No. 1 (the “Amendment”) to the Report of Foreign Private Issuer on Form 6-K (the “Original 6-K”), originally furnished by Global Cord Blood Corporation (the “Company”) to the Securities and Exchange Commission on November 27, 2018 containing the financial results for the three and six months ended September 30, 2018 of the Company, amends the Original 6-K to include an unaudited condensed consolidated statement of changes in equity, an unaudited condensed consolidated statements of cash flows, and notes to the unaudited condensed consolidated financial statements and the applicable interactive data file as Exhibit 101, which provides the unaudited condensed consolidated financial statements in XBRL (eXtensible business reporting language), and to provide for the incorporation by reference described below. No other changes have been made to the Original 6-K. This Amendment does not reflect events that may have occurred subsequent to the original submission date and does not modify or update in any way the disclosures made in the Original 6-K.

This Amendment and each of the exhibits to this Amendment are hereby incorporated by reference into the registration statements on Form F-3 (No. 333-213730 and No. 333-183143) of the Company.

This Amendment contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934. These statements relate to future events or the Company’s future financial performance. The Company has attempted to identify forward-looking statements by terminology including “anticipates”, “believes”, “expects”, “can”, “continue”, “could”, “estimates”, “intends”, “may”, “plans”, “potential”, “predict”, “should” or “will” or the negative of these terms or other comparable terminology. These statements are only predictions, uncertainties and other factors may cause the Company’s actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. The information in this Amendment is not intended to project future performance of the Company. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, the Company does not guarantee future results, levels of activity, performance or achievements. The Company’s expectations are as of the date this Amendment is filed, and the Company does not intend to update any of the forward-looking statements after the date this Amendment is filed to conform these statements to actual results, unless required by law.

2

The forward-looking statements included in this Amendment are subject to risks, uncertainties and assumptions about the Company’s businesses and business environments. These statements reflect the Company’s current views with respect to future events and are not a guarantee of future performance. Actual results of the Company’s operations may differ materially from information contained in the forward-looking statements as a result of risk factors some of which include, among other things: continued compliance with government regulations regarding cord blood banking in the People’s Republic of China, or PRC and any other jurisdiction in which the Company conducts its operations; changing legislation or regulatory environments in the PRC and any other jurisdiction in which the Company conducts its operations; the acceptance by subscribers of the Company’s different pricing and payment options and reaction to the introduction of the Company’s premium-quality pricing strategy; demographic trends in the regions of the PRC in which the Company is the exclusive licensed cord blood banking operator; labor and personnel relations; the existence of a significant shareholder able to influence and direct the corporate policies of the Company; credit risks affecting the Company’s revenue and profitability; changes in the healthcare industry, including those which may result in the use of stem cell therapies becoming redundant or obsolete; the Company’s ability to effectively manage its growth, including maintaining effective controls and procedures and attracting and retaining key management and personnel; changing interpretations of generally accepted accounting principles; the availability of capital resources, including in the form of capital markets financing opportunities, in light of industry developments affecting issuers that have pursued a “reverse merger” with an operating company based in the PRC, the presence of a new majority shareholder, international pressure on trade and currency against the PRC and its potential impact on the PRC consumer behavior, as well as general economic conditions; and other relevant risks detailed in the Company’s filings with the Securities and Exchange Commission in the United States.

3

Results of Operations and Financial Condition

Following this cover page are the unaudited condensed consolidated financial results for the three months and six months ended September 30, 2018 of the Company.

4

Global Cord Blood Corporation and Subsidiaries

Unaudited Condensed Consolidated Balance Sheets

(Amounts expressed in thousands)

		March 31,	September 30,
	Note	2018	2018	2018
		RMB	RMB	US$
ASSETS
Current assets
Cash and cash equivalents		4,250,610	4,611,250	671,410
Accounts receivable, less allowance for doubtful accounts (March 31, 2018: RMB58,227; September 30, 2018: RMB70,817 (US$10,312))		107,818	104,709	15,244
Inventories		27,718	32,538	4,738
Prepaid expenses and other receivables		22,276	25,582	3,725
Total current assets		4,408,422	4,774,079	695,117
Property, plant and equipment, net	3	552,960	543,451	79,128
Non-current deposits		233,115	256,457	37,341
Non-current accounts receivable, less allowance for doubtful accounts (March 31, 2018: RMB69,713; September 30, 2018: RMB70,682 (US$10,291))		101,809	97,798	14,240
Inventories		71,758	74,021	10,778
Intangible assets, net		102,065	99,755	14,525
Investment in equity securities		153,882	126,477	18,415
Other investment		189,129	189,129	27,538
Deferred tax assets		31,295	36,413	5,302
Total assets		5,844,435	6,197,580	902,384
LIABILITIES
Current liabilities
Accounts payable		11,372	21,582	3,142
Accrued expenses and other payables		73,023	83,684	12,184
Deferred revenue		366,373	387,951	56,487
Income tax payable		17,407	18,494	2,693
Total current liabilities		468,175	511,711	74,506
Non-current deferred revenue		1,874,014	1,997,270	290,808
Other non-current liabilities		362,876	386,920	56,337
Deferred tax liabilities		20,628	20,148	2,934
Total liabilities		2,725,693	2,916,049	424,585

5

Global Cord Blood Corporation and Subsidiaries

Unaudited Condensed Consolidated Balance Sheets (Continued)

(Amounts expressed in thousands, except share data)

	March 31,		September 30,
	2018		2018		2018
	RMB		RMB		US$
EQUITY
Shareholders’ equity of Global Cord Blood Corporation
Ordinary shares
- US$0.0001 par value, 250,000,000 shares authorized, 120,961,641 and 120,824,742 shares issued and outstanding as of March 31, 2018 and 121,687,974 and 121,551,075 shares issued and outstanding as of September 30, 2018	83		83		12
Additional paid-in capital	2,053,866		2,101,582		305,996
Treasury stock, at cost (March 31 and September 30, 2018: 136,899 shares, respectively)	(2,815	)	(2,815	)	(410	)
Accumulated other comprehensive losses	(54,654	)	(79,493	)	(11,575	)
Retained earnings	1,116,873		1,254,755		182,695
Total equity attributable to Global Cord Blood Corporation	3,113,353		3,274,112		476,718
Non-controlling interests	5,389		7,419		1,081
Total equity	3,118,742		3,281,531		477,799
Total liabilities and equity	5,844,435		6,197,580		902,384

See accompanying notes to the unaudited condensed consolidated financial statements.

6

Global Cord Blood Corporation and Subsidiaries

Unaudited Condensed Consolidated Statements of Comprehensive Income

(Amounts expressed in thousands, except per share data)

		Three months ended September 30,						Six months ended September 30,
	Note	2017		2018		2018		2017		2018		2018
		RMB		RMB		US$		RMB		RMB		US$
Revenues		234,572		247,104		35,979		458,794		480,925		70,025
Direct costs		(45,644	)	(47,263	)	(6,882	)	(90,426	)	(90,421	)	(13,166	)
Gross profit		188,928		199,841		29,097		368,368		390,504		56,859
Operating expenses
Research and development		(3,664	)	(3,590	)	(523	)	(6,343	)	(6,381	)	(929	)
Sales and marketing		(56,152	)	(51,488	)	(7,497	)	(99,602	)	(102,903	)	(14,983	)
General and administrative		(52,784	)	(39,997	)	(5,824	)	(103,134	)	(81,012	)	(11,796	)
Total operating expenses		(112,600	)	(95,075	)	(13,844	)	(209,079	)	(190,296	)	(27,708	)
Operating income		76,328		104,766		15,253		159,289		200,208		29,151
Other income/(expenses), net
Interest income		5,790		6,405		933		10,617		12,103		1,762
Interest expense		—		—		—		(3,257	)	—		—
Foreign currency exchange gains/(losses)		110		(49	)	(7	)	111		(75	)	(11	)
Unrealized holding loss for equity securities		—		(30,945	)	(4,506	)	—		(40,266	)	(5,863	)
Dividend income		—		976		142		—		976		142
Others		993		(56	)	(8	)	2,142		(815	)	(119	)
Total other income/(expenses), net		6,893		(23,669	)	(3,446	)	9,613		(28,077	)	(4,089	)
Income before income tax		83,221		81,097		11,807		168,902		172,131		25,062
Income tax expense	4	(14,525	)	(14,921	)	(2,173	)	(30,246	)	(31,445	)	(4,578	)
Net income		68,696		66,176		9,634		138,656		140,686		20,484
Net income attributable to non-controlling interests		(1,101	)	(1,062	)	(155	)	(1,926	)	(2,030	)	(296	)
Net income attributable to Global Cord Blood Corporation’s shareholders		67,595		65,114		9,479		136,730		138,656		20,188
Earnings per share:
Attributable to ordinary shares	5
- Basic		0.60		0.54		0.08		1.22		1.15		0.17
- Diluted		0.60		0.53		0.08		1.22		1.14		0.17

7

Global Cord Blood Corporation and Subsidiaries

Unaudited Condensed Consolidated Statements of Comprehensive Income (Continued)

(Amounts expressed in thousands)

	Three months ended September 30,						Six months ended September 30,
	2017		2018		2018		2017		2018		2018
	RMB		RMB		US$		RMB		RMB		US$
Other comprehensive (losses)/ income, net of nil income taxes
- Foreign currency translation adjustments	(8,376	)	14,597		2,125		(20,107	)	37,477		5,457
- Unrealized holding losses in available-for-sale equity securities	(18,562	)	—		—		(30,487	)	—		—
Total other comprehensive (losses)/ income	(26,938	)	14,597		2,125		(50,594	)	37,477		5,457
Comprehensive income	41,758		80,773		11,759		88,062		178,163		25,941
Comprehensive income attributable to non-controlling interests	(1,101	)	(1,062	)	(155	)	(1,926	)	(2,030	)	(296	)
Comprehensive income attributable to Global Cord Blood Corporation’s shareholders	40,657		79,711		11,604		86,136		176,133		25,645

See accompanying notes to the unaudited condensed consolidated financial statements.

8

Global Cord Blood Corporation and Subsidiaries

Unaudited Condensed Consolidated Statement of Changes in Equity

(Amounts expressed in thousands, except share data)

	Global Cord Blood Corporation shareholders
											Accumulated
	Share capital			Additional		Treasury stock					other						Non-
	No. of			paid-in		No. of					comprehensive			Retained			controlling		Total
	shares	Amount		capital		shares		Amount			losses			earnings			interests		equity
		RMB		RMB				RMB			RMB			RMB			RMB		RMB
Balance as of March 31, 2018	120,961,641	83		2,053,866		(136,899	)	(2,815		)	(54,654		)	1,116,873			5,389		3,118,742
Cumulative effect of accounting change due to adoption of Accounting Standards Update 2016-01	—	—		—		—		—			(62,316		)	62,316			—		—
Net income	—	—		—		—		—			—			138,656			2,030		140,686
Other comprehensive income	—	—		—		—		—			37,477			—			—		37,477
Dividend declared to the Company’s shareholders	726,333	—		47,716		—		—			—			(63,090		)	—		(15,374		)
Balance as of September 30, 2018	121,687,974	83		2,101,582		(136,899	)	(2,815		)	(79,493		)	1,254,755			7,419		3,281,531
Balance as of September 30, 2018 - US$		$	12	$	305,996			$	(410	)	$	(11,575	)	$	182,695		$	1,081	$	477,799

See accompanying notes to the unaudited condensed consolidated financial statements.

9

Global Cord Blood Corporation and Subsidiaries

Unaudited Condensed Consolidated Statements of Cash Flows

(Amounts expressed in thousands)

	Six months ended September 30,
	2017		2018		2018
	RMB		RMB		US$
Cash flows from operating activities:
Net cash provided by operating activities	441,710		386,934		56,338
Cash flows from investing activities:
Purchase of property, plant and equipment	(22,045	)	(16,274	)	(2,370	)
Proceeds from disposal of property, plant and equipment	28		326		47
Net cash used in investing activities	(22,017	)	(15,948	)	(2,323	)
Cash flows from financing activities:
Payment for dividends to shareholders	—		(18,173	)	(2,646	)
Net cash used in financing activities	—		(18,173	)	(2,646	)
Effect of foreign currency exchange rate change on cash and cash equivalents	(2,677	)	7,827		1,140
Net increase in cash and cash equivalents	417,016		360,640		52,509
Cash and cash equivalents at beginning of period	3,510,264		4,250,610		618,901
Cash and cash equivalents at end of period	3,927,280		4,611,250		671,410
Supplemental disclosures of cash flow information:
Cash paid for income taxes	32,390		35,940		5,233
Cash paid for interest	1,537		—		—

See accompanying notes to the unaudited condensed consolidated financial statements.

10

Notes to the unaudited condensed consolidated financial statements

(Amounts expressed in thousands, except share data)

1Principal activities and basis of presentation

(a)Principal activities

Global Cord Blood Corporation (formerly known as China Cord Blood Corporation) (the “Company”) and its subsidiaries (collectively the “Group”) are principally engaged in the provision of umbilical cord blood storage and ancillary services in the People’s Republic of China (the “PRC”). As of September 30, 2018, the Group has three operating cord blood banks in the Beijing municipality, the Guangdong province and the Zhejiang province, the PRC. The Company’s shares are listed on the New York Stock Exchange.

The Group provides cord blood testing, processing and storage services under the direction of subscribers for a cord blood processing fee and a storage fee. The Group also tests, processes and stores donated cord blood, and provides matching services to the public for a fee.

(b)Basis of presentation

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”). Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted as permitted by rules and regulations of the U.S. Securities and Exchange Commission (“SEC”). The condensed consolidated balance sheet as of March 31, 2018 was derived from the audited consolidated financial statements of the Company. The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the March 31, 2018 audited consolidated financial statements of the Company included in the Company’s annual report on Form 20-F for the year ended March 31, 2018.

In the opinion of management, all adjustments (which include normal recurring adjustments) necessary to present a fair statement of the financial position as of September 30, 2018, the results of operations for the three months and six months ended September 30, 2017 and 2018, and cash flows for the six months ended September 30, 2017 and 2018 have been made.

For the convenience of the readers, certain amounts as of and for the three months and six months ended September 30, 2018 included in the accompanying unaudited condensed consolidated financial statements have been translated into U.S. dollars at the rate of US$1.00 = RMB6.8680, being the spot exchange rate of U.S. dollars in effect on September 28, 2018 for cable transfers in RMB per U.S. dollar as certified for customs purposes by the Federal Reserve, the central bank of the United States of America. No representation is made that the RMB amounts could have been, or could be, converted into U.S. dollars at that rate or at any other rate on September 30, 2018 or at any other date.

11

2Summary of significant accounting policies

(a)Principles of consolidation

The accompanying unaudited condensed consolidated financial statements include the financial statements of the Company and its consolidated subsidiaries. For consolidated subsidiaries where the Company’s ownership is less than 100%, the portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the Company, are presented as non-controlling interests. All significant intercompany balances and transactions have been eliminated on consolidation.

(b)Use of estimates

The preparation of the consolidated financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant items subject to such estimates and assumptions include the estimate of selling price for individual deliverables in multiple-element revenue arrangements, the estimated future number of successful match units over the estimated weighted average remaining useful life of donated cord blood units, the useful lives of property, plant and equipment and intangible assets, the recoverability of property, plant and equipment and intangible assets, the collectibility of accounts receivables, the realizability of inventories and deferred tax assets.

3Property, plant and equipment, net

Property, plant and equipment, net consist of the following:

	March 31,		September 30,
	2018		2018		2018
	RMB		RMB		US$
Buildings	598,832		598,360		87,123
Leasehold improvements	14,864		14,864		2,164
Machineries	167,310		184,274		26,831
Motor vehicles	18,210		18,903		2,752
Furniture, fixtures and equipment	50,940		52,479		7,641
Construction-in-progress	10,931		3,707		540
	861,087		872,587		127,051
Less: Accumulated depreciation	(308,127	)	(329,136	)	(47,923	)
Total property, plant and equipment, net	552,960		543,451		79,128

Depreciation expense related to property, plant and equipment for the three months ended September 30, 2017 and 2018 was RMB11,199 and RMB12,236 (US$1,782), respectively. Depreciation expense related to property, plant and equipment for the six months ended September 30, 2017 and 2018 was RMB22,796 and RMB24,226 (US$3,528), respectively.

12

4Income tax

The Company’s PRC subsidiaries are subject to PRC statutory income tax rate of 25% unless otherwise specified.

In February 2018, Beijing Jiachenhong Biological Technologies Co., Ltd. (“Beijing Jiachenhong”) received approval from the tax authority on the renewal of its High and New Technology Enterprises (“HNTE”) status which entitled it to the preferential income tax rate of 15% effective retroactively from January 1, 2017 to December 31, 2019.

In March 2017, Guangzhou Municipality Tianhe Nuoya Bio-engineering Co., Ltd. (“Guangzhou Nuoya”) received approval from the tax authority on the renewal of its HNTE status which entitled it to the preferential income tax rate of 15% effective retroactively from January 1, 2016 to December 31, 2018.

In January 2016, Zhejiang Lukou Biotechnology Co., Ltd. (“Zhejiang Lukou”) received approval from the tax authority that it qualified as a HNTE which entitled it to the preferential income tax rate of 15% effective retrospectively from January 1, 2015 to December 31, 2017. Zhejiang Lukou is in the process of reapplication for its HNTE status which will enable it to the preferential income tax rate of 15% from January 1, 2018 to December 31, 2020.

The Enterprise Income Tax Law and its implementation rules also impose a withholding tax at 10%, unless reduced by a tax treaty or agreement, for dividends receivable by non-PRC-resident enterprises from PRC-resident enterprises in respect of earnings accumulated beginning on January 1, 2008. As of September 30, 2018, such undistributed earnings that may be subject to the withholding tax amounted to RMB2,178,063 (US$317,132) and the related unrecognized deferred tax liability was RMB217,806 (US$31,713).

The Company’s effective income tax rates for the three months ended September 30, 2017 and 2018 were 17.5% and 18.4%, and were 17.9% and 18.3% for the six months ended September 30, 2017 and 2018, respectively. The effective income tax rates for the three months and six months ended September 30, 2017 and 2018 differ from the PRC statutory income tax rate of 25% primarily due to the effect of non-PRC entities not being subject to income tax, which is offset by the effect of Beijing Jiachenhong, Guangzhou Nuoya and Zhejiang Lukou’s preferential tax treatments.

As of and for the three months and six months ended September 30, 2018, the Company did not have any material unrecognized tax benefits and thus no interest and penalties related to unrecognized tax benefits were recorded. In addition, the Company does not expect that the amount of unrecognized tax benefits will change significantly within the next twelve months.

13

5Earnings per share

The following table sets forth the computation of basic and diluted earnings per share for the three months and six months ended September 30, 2017 and 2018 respectively:

	Three months ended September 30,
	2017	2018	2018
	RMB	RMB	US$
Numerator:
Net income for basic and diluted net income per share	67,595	65,114	9,479
Denominator:
Weighted average ordinary shares outstanding for basic net income per share	113,524,742	121,156,329	121,156,329
Dilutive effect of scrip dividends	—	544,943	544,943
Weighted average ordinary shares outstanding for diluted net income per share	113,524,742	121,701,272	121,701,272
Earnings per share
- Basic	0.60	0.54	0.08
- Diluted	0.60	0.53	0.08

	Six months ended September 30,
	2017	2018	2018
	RMB	RMB	US$
Numerator:
Net income for basic and diluted net income per share	136,730	138,656	20,188
Denominator:
Weighted average ordinary shares outstanding for basic net income per share	112,196,168	120,991,441	120,991,441
Dilutive effect of scrip dividends	—	301,356	301,356
Weighted average ordinary shares outstanding for diluted net income per share	112,196,168	121,292,797	121,292,797
Earnings per share
- Basic	1.22	1.15	0.17
- Diluted	1.22	1.14	0.17

14

Other Events

On November 27, 2018, the Company issued a press release announcing preliminary unaudited condensed consolidated financial results for the three months and six months ended September 30, 2018. A copy of the press release is attached as Exhibit 99.1.

Exhibits

Exhibit No.	Description
99.1 *	Press Release, dated November 27, 2018
101.INS XBRL	Instance Document
101.SCH XBRL	Taxonomy Extension Schema Document
101.CAL XBRL	Taxonomy Extension Calculation Linkbase Document
101.DEF XBRL	Taxonomy Extension Definition Linkbase Document
101.LAB XBRL	Taxonomy Extension Label Linkbase Document
101.PRE XBRL	Taxonomy Extension Presentation Linkbase Document

* Previously filed

15

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	GLOBAL CORD BLOOD CORPORATION
	By:	/s/ Albert Chen
	Name:	Albert Chen
	Title:	Chief Financial Officer
Dated: December 7, 2018

16

XML

Document and Entity Information	6 Months Ended
	Sep. 30, 2018
Document and Entity Information
Document Type	6-K/A
Amendment Flag	false
Document Period End Date	Sep. 30, 2018
Entity Registrant Name	Global Cord Blood Corp
Entity Central Index Key	0001467808
Current Fiscal Year End Date	--03-31
Document Fiscal Year Focus	2019
Document Fiscal Period Focus	Q2
Entity Filer Category	Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Current Reporting Status	Yes

XML

Unaudited Condensed Consolidated Balance Sheets ¥ in Thousands, $ in Thousands	Sep. 30, 2018 USD ($)	Sep. 30, 2018 CNY (¥)	Mar. 31, 2018 CNY (¥)
Current assets
Cash and cash equivalents	$ 671,410	¥ 4,611,250	¥ 4,250,610
Accounts receivable, less allowance for doubtful accounts (March 31, 2018: RMB58,227; September 30, 2018: RMB70,817 (US$10,312))	15,244	104,709	107,818
Inventories	4,738	32,538	27,718
Prepaid expenses and other receivables	3,725	25,582	22,276
Total current assets	695,117	4,774,079	4,408,422
Property, plant and equipment, net	79,128	543,451	552,960
Non-current deposits	37,341	256,457	233,115
Non-current accounts receivable, less allowance for doubtful accounts (March 31, 2018: RMB69,713; September 30, 2018: RMB70,682 (US$10,291))	14,240	97,798	101,809
Inventories	10,778	74,021	71,758
Intangible assets, net	14,525	99,755	102,065
Investment in equity securities	18,415	126,477	153,882
Other investment	27,538	189,129	189,129
Deferred tax assets	5,302	36,413	31,295
Total assets	902,384	6,197,580	5,844,435
Current liabilities
Accounts payable	3,142	21,582	11,372
Accrued expenses and other payables	12,184	83,684	73,023
Deferred revenue	56,487	387,951	366,373
Income tax payable	2,693	18,494	17,407
Total current liabilities	74,506	511,711	468,175
Non-current deferred revenue	290,808	1,997,270	1,874,014
Other non-current liabilities	56,337	386,920	362,876
Deferred tax liabilities	2,934	20,148	20,628
Total liabilities	424,585	2,916,049	2,725,693
Shareholders' equity of Global Cord Blood Corporation
Ordinary shares - US$0.0001 par value, 250,000,000 shares authorized, 120,961,641 and 120,824,742 shares issued and outstanding as of March 31, 2018 and 121,687,974 and 121,551,075 shares issued and outstanding as of September 30, 2018	12	83	83
Additional paid-in capital	305,996	2,101,582	2,053,866
Treasury stock, at cost (March 31 and September 30, 2018: 136,899 shares, respectively)	(410)	(2,815)	(2,815)
Accumulated other comprehensive losses	(11,575)	(79,493)	(54,654)
Retained earnings	182,695	1,254,755	1,116,873
Total equity attributable to Global Cord Blood Corporation	476,718	3,274,112	3,113,353
Non-controlling interests	1,081	7,419	5,389
Total equity	477,799	3,281,531	3,118,742
Total liabilities and equity	$ 902,384	¥ 6,197,580	¥ 5,844,435

XML

Unaudited Condensed Consolidated Balance Sheets (Parenthetical) ¥ in Thousands, $ in Thousands	Sep. 30, 2018 USD ($) $ / shares shares	Sep. 30, 2018 CNY (¥) shares	Mar. 31, 2018 $ / shares	Mar. 31, 2018 CNY (¥) shares
Unaudited Condensed Consolidated Balance Sheets
Accounts receivable, allowance for doubtful accounts	$ 10,312	¥ 70,817		¥ 58,227
Non-current accounts receivable, allowance for doubtful accounts	$ 10,291	¥ 70,682		¥ 69,713
Ordinary shares, par value per share | $ / shares	$ 0.0001		$ 0.0001
Ordinary shares, shares authorized	250,000,000	250,000,000		250,000,000
Ordinary shares, shares issued	121,687,974	121,687,974		120,961,641
Ordinary shares, shares outstanding	121,551,075	121,551,075		120,824,742
Treasury stock, shares	136,899	136,899		136,899

XML

Unaudited Condensed Consolidated Statements of Comprehensive Income ¥ in Thousands, $ in Thousands	3 Months Ended			6 Months Ended
	Sep. 30, 2018 USD ($) $ / shares	Sep. 30, 2018 CNY (¥) ¥ / shares	Sep. 30, 2017 CNY (¥) ¥ / shares	Sep. 30, 2018 USD ($) $ / shares	Sep. 30, 2018 CNY (¥) ¥ / shares	Sep. 30, 2017 CNY (¥) ¥ / shares
Unaudited Condensed Consolidated Statements of Comprehensive Income
Revenues	$ 35,979	¥ 247,104	¥ 234,572	$ 70,025	¥ 480,925	¥ 458,794
Direct costs	(6,882)	(47,263)	(45,644)	(13,166)	(90,421)	(90,426)
Gross profit	29,097	199,841	188,928	56,859	390,504	368,368
Operating (expenses)/income, net
Research and development	(523)	(3,590)	(3,664)	(929)	(6,381)	(6,343)
Sales and marketing	(7,497)	(51,488)	(56,152)	(14,983)	(102,903)	(99,602)
General and administrative	(5,824)	(39,997)	(52,784)	(11,796)	(81,012)	(103,134)
Total operating expenses, net	(13,844)	(95,075)	(112,600)	(27,708)	(190,296)	(209,079)
Operating income	15,253	104,766	76,328	29,151	200,208	159,289
Other income/(expenses), net
Interest income	933	6,405	5,790	1,762	12,103	10,617
Interest expense						(3,257)
Foreign currency exchange gains/(losses)	(7)	(49)	110	(11)	(75)	111
Unrealized holding loss for equity securities	(4,506)	(30,945)		(5,863)	(40,266)
Dividend income	142	976		142	976
Others	(8)	(56)	993	(119)	(815)	2,142
Total other income/(expenses), net	(3,446)	(23,669)	6,893	(4,089)	(28,077)	9,613
Income before income tax	11,807	81,097	83,221	25,062	172,131	168,902
Income tax expense	(2,173)	(14,921)	(14,525)	(4,578)	(31,445)	(30,246)
Net income	9,634	66,176	68,696	20,484	140,686	138,656
Net income attributable to non-controlling interests	(155)	(1,062)	(1,101)	(296)	(2,030)	(1,926)
Net income attributable to Global Cord Blood Corporation's shareholders	$ 9,479	¥ 65,114	¥ 67,595	$ 20,188	¥ 138,656	¥ 136,730
Earnings per share:
Basic | (per share)	$ 0.08	¥ 0.54	¥ 0.60	$ 0.17	¥ 1.15	¥ 1.22
Diluted | (per share)	$ 0.08	¥ 0.53	¥ 0.60	$ 0.17	¥ 1.14	¥ 1.22
Other comprehensive (losses)/income, net of nil income taxes
Foreign currency translation adjustments	$ 2,125	¥ 14,597	¥ (8,376)	$ 5,457	¥ 37,477	¥ (20,107)
Unrealized holding gains/(losses) in available-for-sale equity securities			(18,562)			(30,487)
Total other comprehensive (losses)/income	2,125	14,597	(26,938)	5,457	37,477	(50,594)
Comprehensive income	11,759	80,773	41,758	25,941	178,163	88,062
Comprehensive income attributable to non-controlling interests	(155)	(1,062)	(1,101)	(296)	(2,030)	(1,926)
Comprehensive income attributable to Global Cord Blood Corporation's shareholders	$ 11,604	¥ 79,711	¥ 40,657	$ 25,645	¥ 176,133	¥ 86,136

XML

Unaudited Condensed Consolidated Statements of Comprehensive Income (Parenthetical) - CNY (¥) ¥ in Thousands	3 Months Ended		6 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Other comprehensive losses
Other comprehensive (losses)/income, income taxes	¥ 0	¥ 0	¥ 0	¥ 0

XML

Unaudited Condensed Consolidated Statement of Changes in Equity - 6 months ended Sep. 30, 2018 ¥ in Thousands, $ in Thousands	Share capital USD ($) shares	Share capital CNY (¥) shares	Additional paid-in capital USD ($)	Additional paid-in capital CNY (¥)	Treasury stock USD ($) shares	Treasury stock CNY (¥) shares	Accumulated other comprehensive losses USD ($)	Accumulated other comprehensive losses CNY (¥)	Retained earnings USD ($)	Retained earnings CNY (¥)	Non-controlling interests USD ($)	Non-controlling interests CNY (¥)	USD ($) shares	CNY (¥) shares
Balance at Mar. 31, 2018 | ¥		¥ 83		¥ 2,053,866		¥ (2,815)		¥ (54,654)		¥ 1,116,873		¥ 5,389		¥ 3,118,742
Balance, shares at Mar. 31, 2018 | shares	120,961,641	120,961,641			(136,899)	(136,899)							120,824,742	120,824,742
Net income										138,656		2,030	$ 20,484	¥ 140,686
Other comprehensive income								37,477					5,457	37,477
Dividend declared to the Company's shareholders | ¥				47,716						(63,090)				(15,374)
Dividend declared to the Company's shareholders (in shares) | shares	726,333	726,333
Balance at Sep. 30, 2018	$ 12	¥ 83	$ 305,996	¥ 2,101,582	$ (410)	¥ (2,815)	$ (11,575)	(79,493)	$ 182,695	1,254,755	$ 1,081	¥ 7,419	$ 477,799	¥ 3,281,531
Balance, shares at Sep. 30, 2018 | shares	121,687,974	121,687,974			(136,899)	(136,899)							121,551,075	121,551,075
Cumulative effect of accounting change due to adoption of Accounting Standards Update 2016-01 | ASU 2016-01 | ¥								¥ (62,316)		¥ 62,316

XML

Unaudited Condensed Consolidated Statements of Cash Flows ¥ in Thousands, $ in Thousands	6 Months Ended
	Sep. 30, 2018 USD ($)	Sep. 30, 2018 CNY (¥)	Sep. 30, 2017 CNY (¥)
Cash flows from operating activities:
Net cash provided by operating activities	$ 56,338	¥ 386,934	¥ 441,710
Cash flows from investing activities:
Purchase of property, plant and equipment	(2,370)	(16,274)	(22,045)
Proceeds from disposal of property, plant and equipment	47	326	28
Net cash used in investing activities	(2,323)	(15,948)	(22,017)
Cash flows from financing activities:
Payment for dividends to shareholders	(2,646)	(18,173)
Net cash used in financing activities	(2,646)	(18,173)
Effect of foreign currency exchange rate change on cash and cash equivalents	1,140	7,827	(2,677)
Net increase in cash and cash equivalents	52,509	360,640	417,016
Cash and cash equivalents at beginning of year	618,901	4,250,610	3,510,264
Cash and cash equivalents at end of year	671,410	4,611,250	3,927,280
Supplemental disclosures of cash flow information:
Cash paid for income taxes	$ 5,233	¥ 35,940	32,390
Cash paid for interest			¥ 1,537

XML

Principal activities and basis of presentation

6 Months Ended

Sep. 30, 2018

Principal activities and basis of presentation

Principal activities and basis of presentation

1           Principal activities and basis of presentation

(a)Principal activities

Global Cord Blood Corporation (formerly known as China Cord Blood Corporation) (the “Company”) and its subsidiaries (collectively the “Group”) are principally engaged in the provision of umbilical cord blood storage and ancillary services in the People’s Republic of China (the “PRC”). As of September 30, 2018, the Group has three operating cord blood banks in the Beijing municipality,  the Guangdong province and the Zhejiang province, the PRC. The Company’s shares are listed on the New York Stock Exchange.

The Group provides cord blood testing, processing and storage services under the direction of subscribers for a cord blood processing fee and a storage fee. The Group also tests, processes and stores donated cord blood, and provides matching services to the public for a fee.

(b)Basis of presentation

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”). Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted as permitted by rules and regulations of the U.S. Securities and Exchange Commission (“SEC”). The condensed consolidated balance sheet as of March 31, 2018 was derived from the audited consolidated financial statements of the Company. The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the March 31, 2018 audited consolidated financial statements of the Company included in the Company’s annual report on Form 20-F for the year ended March 31, 2018.

In the opinion of management, all adjustments (which include normal recurring adjustments) necessary to present a fair statement of the financial position as of September 30, 2018, the results of operations for the three months and six months ended September 30, 2017 and 2018, and cash flows for the six months ended September 30, 2017 and 2018 have been made.

For the convenience of the readers, certain amounts as of and for the three months and six months ended September 30, 2018 included in the accompanying unaudited condensed consolidated financial statements have been translated into U.S. dollars at the rate of US$1.00 = RMB6.8680, being the spot exchange rate of U.S. dollars in effect on September 28, 2018 for cable transfers in RMB per U.S. dollar as certified for customs purposes by the Federal Reserve, the central bank of the United States of America. No representation is made that the RMB amounts could have been, or could be, converted into U.S. dollars at that rate or at any other rate on September 30, 2018 or at any other date.

XML

Summary of significant accounting policies

6 Months Ended

Sep. 30, 2018

Summary of significant accounting policies

Summary of significant accounting policies

2           Summary of significant accounting policies

(a)Principles of consolidation

The accompanying unaudited condensed consolidated financial statements include the financial statements of the Company and its consolidated subsidiaries. For consolidated subsidiaries where the Company’s ownership is less than 100%, the portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the Company, are presented as non-controlling interests. All significant intercompany balances and transactions have been eliminated on consolidation.

(b)Use of estimates

The preparation of the consolidated financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant items subject to such estimates and assumptions include the estimate of selling price for individual deliverables in multiple-element revenue arrangements, the estimated future number of successful match units over the estimated weighted average remaining useful life of donated cord blood units, the useful lives of property, plant and equipment and intangible assets, the recoverability of property, plant and equipment and intangible assets, the collectibility of accounts receivables, the realizability of inventories and deferred tax assets.

XML

Property, plant and equipment, net

6 Months Ended

Sep. 30, 2018

Property, plant and equipment, net

Property, plant and equipment, net

3           Property, plant and equipment, net

Property, plant and equipment, net consist of the following:

	March 31,	September30,
	2018	2018	2018
	RMB	RMB	US$
Buildings	598,832	598,360	87,123
Leasehold improvements	14,864	14,864	2,164
Machineries	167,310	184,274	26,831
Motor vehicles	18,210	18,903	2,752
Furniture, fixtures and equipment	50,940	52,479	7,641
Construction-in-progress	10,931	3,707	540
	861,087	872,587	127,051
Less: Accumulated depreciation	(308,127)	(329,136)	(47,923)
Total property, plant and equipment, net	552,960	543,451	79,128

Depreciation expense related to property, plant and equipment for the three months ended September 30, 2017 and 2018 was RMB11,199 and RMB12,236 (US$1,782), respectively. Depreciation expense related to property, plant and equipment for the six months ended September 30, 2017 and 2018 was RMB22,796 and RMB24,226 (US$3,528), respectively.

XML

Income tax

6 Months Ended

Sep. 30, 2018

Income tax

Income tax

4Income tax

The Company’s PRC subsidiaries are subject to PRC statutory income tax rate of 25% unless otherwise specified.

In February 2018, Beijing Jiachenhong Biological Technologies Co., Ltd. (“Beijing Jiachenhong”) received approval from the tax authority on the renewal of its High and New Technology Enterprises (“HNTE”) status which entitled it to the preferential income tax rate of 15% effective retroactively from January 1, 2017 to December 31, 2019.

In March 2017, Guangzhou Municipality Tianhe Nuoya Bio-engineering Co., Ltd. (“Guangzhou Nuoya”) received approval from the tax authority on the renewal of its HNTE status which entitled it to the preferential income tax rate of 15% effective retroactively from January 1, 2016 to December 31, 2018.

In January 2016, Zhejiang Lukou Biotechnology Co., Ltd. (“Zhejiang Lukou”) received approval from the tax authority that it qualified as a HNTE which entitled it to the preferential income tax rate of 15% effective retrospectively from January 1, 2015 to December 31, 2017. Zhejiang Lukou is in the process of reapplication for its HNTE status which will enable it to the preferential income tax rate of 15% from January 1, 2018 to December 31, 2020.

The Enterprise Income Tax Law and its implementation rules also impose a withholding tax at 10%, unless reduced by a tax treaty or agreement, for dividends receivable by non-PRC-resident enterprises from PRC-resident enterprises in respect of earnings accumulated beginning on January 1, 2008. As of September 30, 2018, such undistributed earnings that may be subject to the withholding tax amounted to RMB2,178,063 (US$317,132) and the related unrecognized deferred tax liability was RMB217,806 (US$31,713).

The Company’s effective income tax rates for the three months ended September 30, 2017 and 2018 were 17.5% and 18.4%, and were 17.9% and 18.3% for the six months ended September 30, 2017 and 2018, respectively. The effective income tax rates for the three months and six months ended September 30, 2017 and 2018 differ from the PRC statutory income tax rate of 25% primarily due to the effect of non-PRC entities not being subject to income tax, which is offset by the effect of Beijing Jiachenhong, Guangzhou Nuoya and Zhejiang Lukou’s preferential tax treatments.

As of and for the three months and six months ended September 30, 2018, the Company did not have any material unrecognized tax benefits and thus  no interest and penalties related to unrecognized tax benefits were recorded. In addition, the Company does not expect that the amount of unrecognized tax benefits will change significantly within the next twelve months.

XML

Earnings per share

6 Months Ended

Sep. 30, 2018

Earnings per share

Earnings per share

5           Earnings per share

The following table sets forth the computation of basic and diluted earnings per share for the three months and six months ended September 30, 2017 and 2018 respectively:

	Three months ended September 30,
	2017	2018	2018
	RMB	RMB	US$
Numerator:
Net income for basic and diluted net income per share	67,595	65,114	9,479
Denominator:
Weighted average ordinary shares outstanding for basic net income per share	113,524,742	121,156,329	121,156,329
Dilutive effect of scrip dividends	—	544,943	544,943
Weighted average ordinary shares outstanding for diluted net income per share	113,524,742	121,701,272	121,701,272
Earnings per share
- Basic	0.60	0.54	0.08
- Diluted	0.60	0.53	0.08

	Six months ended September30,
	2017	2018	2018
	RMB	RMB	US$
Numerator:
Net income for basic and diluted net income per share	136,730	138,656	20,188
Denominator:
Weighted average ordinary shares outstanding for basic net income per share	112,196,168	120,991,441	120,991,441
Dilutive effect of scrip dividends	—	301,356	301,356
Weighted average ordinary shares outstanding for diluted net income per share	112,196,168	121,292,797	121,292,797
Earnings per share
- Basic	1.22	1.15	0.17
- Diluted	1.22	1.14	0.17

XML

Summary of significant accounting policies (Policies)

6 Months Ended

Sep. 30, 2018

Summary of significant accounting policies

Principles of consolidation

(a)Principles of consolidation

The accompanying unaudited condensed consolidated financial statements include the financial statements of the Company and its consolidated subsidiaries. For consolidated subsidiaries where the Company’s ownership is less than 100%, the portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the Company, are presented as non-controlling interests. All significant intercompany balances and transactions have been eliminated on consolidation.

Use of estimates

(b)Use of estimates

The preparation of the consolidated financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant items subject to such estimates and assumptions include the estimate of selling price for individual deliverables in multiple-element revenue arrangements, the estimated future number of successful match units over the estimated weighted average remaining useful life of donated cord blood units, the useful lives of property, plant and equipment and intangible assets, the recoverability of property, plant and equipment and intangible assets, the collectibility of accounts receivables, the realizability of inventories and deferred tax assets.

XML

Property, plant and equipment, net (Tables)

6 Months Ended

Sep. 30, 2018

Property, plant and equipment, net

Schedule of property, plant and equipment, net

	March 31,	September30,
	2018	2018	2018
	RMB	RMB	US$
Buildings	598,832	598,360	87,123
Leasehold improvements	14,864	14,864	2,164
Machineries	167,310	184,274	26,831
Motor vehicles	18,210	18,903	2,752
Furniture, fixtures and equipment	50,940	52,479	7,641
Construction-in-progress	10,931	3,707	540
	861,087	872,587	127,051
Less: Accumulated depreciation	(308,127)	(329,136)	(47,923)
Total property, plant and equipment, net	552,960	543,451	79,128

XML

Earnings per share (Tables)

6 Months Ended

Sep. 30, 2018

Earnings per share

Schedule of basic and diluted earnings per share

	Three months ended September 30,
	2017	2018	2018
	RMB	RMB	US$
Numerator:
Net income for basic and diluted net income per share	67,595	65,114	9,479
Denominator:
Weighted average ordinary shares outstanding for basic net income per share	113,524,742	121,156,329	121,156,329
Dilutive effect of scrip dividends	—	544,943	544,943
Weighted average ordinary shares outstanding for diluted net income per share	113,524,742	121,701,272	121,701,272
Earnings per share
- Basic	0.60	0.54	0.08
- Diluted	0.60	0.53	0.08

	Six months ended September30,
	2017	2018	2018
	RMB	RMB	US$
Numerator:
Net income for basic and diluted net income per share	136,730	138,656	20,188
Denominator:
Weighted average ordinary shares outstanding for basic net income per share	112,196,168	120,991,441	120,991,441
Dilutive effect of scrip dividends	—	301,356	301,356
Weighted average ordinary shares outstanding for diluted net income per share	112,196,168	121,292,797	121,292,797
Earnings per share
- Basic	1.22	1.15	0.17
- Diluted	1.22	1.14	0.17

XML

Principal activities and basis of presentation (Details)	Sep. 30, 2018 item	Sep. 28, 2018 ¥ / $
Principal activities and basis of presentation
Number of cord blood banking licenses issued that are held by the Company | item	3
Foreign currency convenience translation rate | ¥ / $		6.8680

XML

Property, plant and equipment, net - Schedule (Details) ¥ in Thousands, $ in Thousands	Sep. 30, 2018 USD ($)	Sep. 30, 2018 CNY (¥)	Mar. 31, 2018 CNY (¥)
Property, plant and equipment, net
Property, plant and equipment	$ 127,051	¥ 872,587	¥ 861,087
Less: Accumulated depreciation	(47,923)	(329,136)	(308,127)
Total property, plant and equipment, net	79,128	543,451	552,960
Buildings
Property, plant and equipment, net
Property, plant and equipment	87,123	598,360	598,832
Leasehold improvements
Property, plant and equipment, net
Property, plant and equipment	2,164	14,864	14,864
Machineries
Property, plant and equipment, net
Property, plant and equipment	26,831	184,274	167,310
Motor vehicles
Property, plant and equipment, net
Property, plant and equipment	2,752	18,903	18,210
Furniture, fixtures and equipment
Property, plant and equipment, net
Property, plant and equipment	7,641	52,479	50,940
Construction-in-progress
Property, plant and equipment, net
Property, plant and equipment	$ 540	¥ 3,707	¥ 10,931

XML

Property, plant and equipment, net - Depreciation expense (Details) ¥ in Thousands, $ in Thousands	3 Months Ended			6 Months Ended
	Sep. 30, 2018 USD ($)	Sep. 30, 2018 CNY (¥)	Sep. 30, 2017 CNY (¥)	Sep. 30, 2018 USD ($)	Sep. 30, 2018 CNY (¥)	Sep. 30, 2017 CNY (¥)
Property, plant and equipment, net
Depreciation expense	$ 1,782	¥ 12,236	¥ 11,199	$ 3,528	¥ 24,226	¥ 22,796

XML

Income tax (Details) ¥ in Thousands, $ in Thousands	3 Months Ended		6 Months Ended		36 Months Ended
	Sep. 30, 2018 CNY (¥)	Sep. 30, 2017	Sep. 30, 2018 CNY (¥)	Sep. 30, 2017	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017	Sep. 30, 2018 USD ($)	Sep. 30, 2018 CNY (¥)
Income tax
Effective income tax rate	18.40%	17.50%	18.30%	17.90%
Undistributed earnings that may be subject to the withholding tax									$ 317,132	¥ 2,178,063
Unrecognized deferred tax liability from unremitted earnings of PRC subsidiaries									$ 31,713	¥ 217,806
Interest and penalties related to unrecognized tax benefits	¥ 0		¥ 0
The PRC
Income tax
Statutory income tax rate			25.00%
Withholding tax rate			10.00%
Beijing Jiachenhong | Forecast
Income tax
HNTE preferential tax rate						15.00%
Guangzhou Nuoya | Forecast
Income tax
HNTE preferential tax rate							15.00%
Zhejiang Lukou
Income tax
HNTE preferential tax rate								15.00%
Zhejiang Lukou | Forecast
Income tax
HNTE preferential tax rate					15.00%

XML

Earnings per share (Details) ¥ / shares in Units, $ / shares in Units, ¥ in Thousands, $ in Thousands	3 Months Ended			6 Months Ended
	Sep. 30, 2018 USD ($) $ / shares shares	Sep. 30, 2018 CNY (¥) ¥ / shares shares	Sep. 30, 2017 CNY (¥) ¥ / shares shares	Sep. 30, 2018 USD ($) $ / shares shares	Sep. 30, 2018 CNY (¥) ¥ / shares shares	Sep. 30, 2017 CNY (¥) ¥ / shares shares
Numerator:
Net income for basic and diluted net income per share	$ 9,479	¥ 65,114	¥ 67,595	$ 20,188	¥ 138,656	¥ 136,730
Denominator:
Weighted average ordinary shares outstanding for basic net income per share	121,156,329	121,156,329	113,524,742	120,991,441	120,991,441	112,196,168
Dilutive effect of scrip dividends	544,943	544,943		301,356	301,356
Weighted average ordinary shares outstanding for diluted net income per share	121,701,272	121,701,272	113,524,742	121,292,797	121,292,797	112,196,168
Earnings per share
Basic | (per share)	$ 0.08	¥ 0.54	¥ 0.60	$ 0.17	¥ 1.15	¥ 1.22
Diluted | (per share)	$ 0.08	¥ 0.53	¥ 0.60	$ 0.17	¥ 1.14	¥ 1.22